Low MITF expression in melanomas has previously been linked to increased expression of RTKs such as AXL, EGFR, and PDGFRβ, which activate immediate–early signaling, causing resistance to RAF/MEK inhibitors (Muller et al, 2014). The gene discussed is EGFR; the disease is melanoma.